Outcomes and Follow-up after Hepatitis C Eradication with DAAs

EASL Guidelines advise hepatitis C virus (HCV) RNA in PW1bs or men who have sex with men with ongoing risk behavior (A1). Current direct-acting antivirals (DAAs)-based regimens are highly effective and safe. Early treatment halt the progression to cirrhosis and allow for a decrease in healthcare costs. HCV eradication can prevent the complications of liver cirrhosis and extrahepatic manifestations. Noninvasive tests can predict the onset of complications. Ideal followup after sustained virologic response in patients with advanced liver disease and cirrhosis is still debated.